More Generic Launches For Mylan
Mylan Pharmaceuticals Inc., a subsidiary of generic pharma major Mylan Inc. (NYSE:MYL), recently announced that it has received final approval from the U.S. Food & Drug Administration (FDA) for its generic version of Boehringer Ingelheim’s Viramune (nevirapine). Viramune is approved for HIV-1 infection in combination with antiretroviral (ARV) treatment. According to IMS Health, Viramune generated [...]
Mylan Pharmaceuticals Inc., a subsidiary of generic pharma major Mylan Inc. (NYSE:MYL), recently announced that it has received final approval from the U.S. Food & Drug Administration (FDA) for its generic version of Boehringer Ingelheim’s Viramune (nevirapine).
Viramune is approved for HIV-1 infection in combination with antiretroviral (ARV) treatment. According to IMS Health, Viramune generated U.S. revenues of approximately $116.6 million for the 12 months ending March 31, 2012.
Apart … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards